Non-diagnostic AIDS-associated malignant neoplasms

Acquired immunodeficiency syndrome (AIDS) malignancies are a well-recognised and potentially lethal consequence of the disease. Three malignancies have shown an increased incidence and qualify as AIDS-defining conditions when they occur in conjunction with HIV infection: Kaposi's sarcoma (KS), non-Hodgkin's lymphoma (NHL), including primary central nervous system lymphoma (PCNSL), and invasive cancer of the cervix. Data from the AIDS-Cancer Match Registry Study Group1 demonstrate the relative increased risk for the development of the three current AIDS-defining cancers, but also suggest an increase in Hodgkin's disease (HD) and, to a lesser degree, anal carcinoma, testicular seminoma and lip cancer. Highly active antiretroviral therapy (HAART) has exerted an effect on the incidence of malignancies. Since its implementation the incidence of KS and NHL has declined substantially, but there has been no major change in the incidence of cervical cancer or Hodgkin's disease.2 The most common source of morbidity and mortality from AIDS has been opportunistic infections (OIs). Since the improvement in survival of patients with HIV infection, due to better prevention, the treatment of infectious complications and HAART, there appears to have been an increase in the incidence of malignant tumours, in particular those non-diagnostic of AIDS. Southern African Journal of HIV Medicine Vol. 8 (1) 2007: pp. 11-1

Palliative treatment for HIV-related Kaposi's sarcoma

No Abstract

Extranodal presentation in patients with acquired immunodeficiency syndrome non-Hodgkin\'s lymphoma (AIDS-NHL)

Kaposi's sarcoma, non-Hodgkin's lymphoma (NHL), including primary central nervous system lymphoma (PCNSL), and cervical cancer define the acquired immune deficiency syndrome (AIDS). NHL is the second most common malignancy associated with HIV infection. The clinical presentation varies, and while patients may present with symptomatic lymphadenopathy, many have extranodal disease. Extranodal lymphomas arise from tissue other than lymph nodes and even sites that normally contain no lymphoid tissue. These lymphomas are referred to as extranodal lymphomas and can arise in almost any organ. AIDS-NHL may present at any point in the course of immunosuppression. This report deals with three case studies that illustrate the spectrum and variety of extranodal presentations in patients with AIDS-NHL. Southern African Journal of HIV Medicine Vol. 6 (1) 2005: pp. 37-4

Pregnancy in a patient with advanced human immunodeficiency virus (HIV) and Kaposi's sarcoma

Please help populate SUNScholar with the full text of SU research output. Also - should you need this item urgently, please send us the details and we will try to get hold of the full text as quick possible. E-mail to [email protected]. Thank you.Geneeskunde en GesondheidswetenskappeStralingsonkologi

Persistent pleural effusion in an HIV patient treated for tuberculosis

[No abstract available]Articl

Extranodal presentation in patients with acquired immunodeficiency syndrome non-hodgkin's lymphoma (AIDS-NHL)

Kaposi's sarcoma, non-Hodgkin's lymphoma (NHL), including primary central nervous system lymphoma (PCNSL), and cervical cancer define the acquired immune deficiency syndrome (AIDS). NHL is the second most common malignancy associated with HIV infection. The clinical presentation varies, and while patients may present with asymptomatic lymphadenopathy, many have extranodal disease. Extranodal lymphomas arise from tissue other than lymph nodes and even sites that normally contain no lymphoid tissue. These lymphomas are referred to as extranodal lymphomas and can arise in almost any organ. AIDS-NHL may present at any point in the course of immunosuppression. This report deals with three case studies that illustrate the spectrum and variety of extranodal presentations in patients with AIDS-NHL.Articl

Non-diagnostic aids-associated malignant neoplasms

Acquired immunodeficiency syndrome (AIDS) malignancies are a well-recognised and potentially lethal consequence of the disease. Three malignancies have shown an increased incidence and qualify as AIDS-defining conditions when they occur in conjunction with HIV infection: Kaposi's sarcoma (KS), non-Hodgkin's lymphoma (NHL), including primary central nervous system lymphoma (PCNSL), and invasive cancer of the cervix. Data from the AIDS-Cancer Match Registry Study Group demonstrate the relative increased risk for the development of the three current AIDS-defining cancers, but also suggest an increase in Hodgkin's disease (HD) and, to a lesser degree, anal carcinoma, testicular seminoma and lip cancer. Highly active antiretroviral therapy (HAART) has exerted an effect on the incidence of malignancies. Since its implementation the incidence of KS and NHL has declined substantially, but there has been no major change in the incidence of cervical cancer or Hodgkin's disease. The most common source of morbidity and mortality from AIDS has been opportunistic infections (OIs). Since the improvement in survival of patients with HIV infection, due to better prevention, the treatment of infectious complications and HAART, there appears to have been an increase in the incidence of malignant tumours, in particular those non-diagnostic of AIDS.Articl

The radiological appearance of metastatic lesions. Abstract 206.

Please help us populate SUNScholar with the post print version of this article. It can be e-mailed to: [email protected]

Palliative treatment for HIV-related Kaposi's sarcoma

Objective. To evaluate palliative treatment with chemotherapy and/or radiotherapy in patients with HIV-related Kaposi's sarcoma (KS). The primary end-point was symptom relief; the secondary end-point was tumour response to treatment and overall survival. Methods. This study includes 100 patients with HIV-related KS. Combination chemotherapy was administered with ABV (doxorubicin, bleomycin and vincristine) (33 patients), or vinblastine and bleomycin (Vbl-B) (48 patients), depending on the CD4+ count at presentation. Radiotherapy was administered to 31 patients. Results. Symptomatic relief was noted within 4 weeks of chemotherapy and response after 8 weeks. Twenty-nine patients (29%) had partial responses, 8 patients (8%) achieved complete responses, and 37 patients (37%) had stable disease. Twenty-six patients (26%) had disease progression. The response rate was 37%, with clinical benefit achieved in 74% of patients. Patients who received radiation therapy for bleeding and painful ulcers had complete responses. Twenty-seven patients (27%) received 8 Gray (Gy) single fractions. Two lower-half bodies (8 Gy) and one upper-half body (6 Gy) were irradiated. Five patients received a course of radiation for nasopharyngeal and skeletal lesions (20 Gy), rectal lesions (30 Gy) and an eyelid lesion (12 Gy). Forty-two patients (42%) are alive, with a median survival of 11.2 months (range 2 - 49 months). Fifty-eight patients (58%) died due to progression of HIV disease or associated opportunistic infections with a median overall survival of 8.8 months (range 1 - 31 months). Conclusion. In the absence of antiretroviral therapy the care and prognosis of HIV-related Kaposi's sarcoma remains dismal. However, symptomatic relief and an improved quality of life can still be offered.Articl

A retrospective analysis of response and survival outcomes following neo-adjuvant chemotherapy in breast cancer patients

Geneeskunde en GesondheidswetenskappeStralingsonkologiePlease help us populate SUNScholar with the post print version of this article. It can be e-mailed to: [email protected]